Main Menu

The collaborative effort between the Jarvis Laboratory at the University of Plymouth and Feldmann's laboratory led to the development and testing of a groundbreaking Cytomegalovirus (CMV)-based vaccine designed to express the Ebola virus glycoprotein. This innovative approach aimed to enhance Ebola virus-specific immunogenicity and efficacy. The Jarvis Laboratory was responsible for the initial design and construction of the vaccine prototype, while Feldmann's team conducted extensive testing for immunogenicity and efficacy using a nonhuman primate model.

This technology summary highlights the pivotal role of replicons, cell lines, and reporter virus particles (RVPs) in advancing Flavivirus research. Replicons, engineered from the viral genome, allow for controlled replication in host cells, while cell lines stably harboring these replicons provide valuable tools for drug discovery and the production of pseudo-infectious virus particles. These RVPs, composed of flavivirus structural proteins, underpin a high-throughput quantitative method for studying antibody-mediated neutralization of infection.

The development of live attenuated vaccines for Japanese encephalitis (JE) represents a groundbreaking technology with the potential to transform vaccination approaches. These vaccines offer the advantage of single-dose administration, simplifying vaccination schedules and reducing logistical challenges.

Researchers have developed a groundbreaking influenza vaccine using a modular nanoparticle platform that displays hemagglutinin (HA) from various influenza strains on either separate or combined particles. Unlike traditional vaccines with limited efficacy due to antigenic mismatch, these novel nanoparticles can be customized to target seasonal strains, offering stronger immune responses and broader protection against multiple subtypes, including those not included in the annual vaccine formulation.

This technology focuses on a groundbreaking approach to enhance the development of HIV/AIDS prevention and treatment strategies. By identifying a previously unrecognized constraint that stabilizes the closed conformation of the crucial HIV-1 envelope glycoprotein gp120, researchers have devised a novel means of blocking HIV-1 entry and fusion using a V1V2 stem mimetic peptide.

Autologous Granulocyte Therapy, a cutting-edge advancement in the treatment of Chronic Granulomatous Disease (CGD), offers a groundbreaking solution to the challenges faced by CGD patients. This innovative technology involves correcting the genetic defects in the patient's own phagocytes by providing the missing messenger RNA (mRNA) required for protein production. These functionally corrected autologous granulocytes can then be reintroduced into the patient's system to combat severe infections.

This technology involves the development of live attenuated vaccine candidates for respiratory syncytial virus (RSV), a significant cause of severe respiratory tract diseases, particularly in infants and young children. The approach focuses on relocating the NS1 and NS2 genes within the RSV genome to downstream positions, resulting in reduced transcription and expression. This gene-shifting strategy allows for controlled attenuation of the virus, avoiding over-attenuation seen with gene deletion. Combining gene shifts with other mutations fine-tunes the level of attenuation.

Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions.

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.